Oncolytic AAV

CuriRx Launches the Advanced Bioprocessing and Analytical Center to Support Biotherapeutic Drug Developers

Retrieved on:

Wednesday, January 26, 2022

View, Analytical Center for the Government of the Russian Federation, CDMO, Monoclonal antibody, AAV, Oncolytic AAV, Multimedia, Control, Method, Doctor of Philosophy, Mab, A-DNA, Vaccine, Oligonucleotide, 3D printing, Fine chemical, Takeda

WILMINGTON, Mass., Jan. 26, 2022 /PRNewswire/ -- CuriRx, Inc., a leading contract development and manufacturing organization (CDMO), announced today the launch of the Advanced Bioprocessing and Analytical Center. Led by CuriRx's team of industry experts and state-of-the-art bioprocessing laboratories combined with the CuriLytics ™ Platform's high-resolution analytical instrumentation, the Advanced Bioprocessing and Analytical Center provides end to end support to developers of biotherapeutics.

Key Points:

WILMINGTON, Mass., Jan. 26, 2022 /PRNewswire/ -- CuriRx, Inc ., a leading contract development and manufacturing organization (CDMO), announced today the launch of the Advanced Bioprocessing and Analytical Center.
Led by CuriRx's team of industry experts and state-of-the-art bioprocessing laboratories combined with the CuriLytics Platform's high-resolution analytical instrumentation, the Advanced Bioprocessing and Analytical Center provides end to end support to developers of biotherapeutics.
CuriRx's Advanced Bioprocessing and Analytical Center offers the unique ability to accelerate biotherapeutic drug development and overcome challenges by leveraging their team's decades of bioprocessing experience and the latest methods in upstream and downstream process development.
Dr. Javeri added, "The Advanced Bioprocessing and Analytical Center along with our formulation, lyophilization and analytical testing services provides complete end to end support."

CuriRx Launches CuriLytics™ Platform to Provide CMC Analytical Services to Support Complex Biotherapeutic Development Using High Resolution Mass Spectrometry

Retrieved on:

Tuesday, September 21, 2021

Vaccine, CMC, A-DNA, Oncolytic AAV, Multimedia, Orbitrap, Monoclonal antibody, Oligonucleotide, Mab, Control, Risk, View, Drug development, CRO, AAV, Fine chemical, Medical device

Led by CuriRx's team of industry experts and state-of-the-art high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics platform provides support to developers of complex biotherapeutics.

Key Points:

Led by CuriRx's team of industry experts and state-of-the-art high-resolution Orbitrap mass spectrometry instrumentation, the CuriLytics platform provides support to developers of complex biotherapeutics.
Improving and de-risking the overall drug development path from Phase I clinical trials through approval requires advanced analyses of critical quality attributes.
The CuriLytics platform is designed to provide confidence to biotherapeutic developers from discovery to regulatory approval."
CuriRx is planning to hold a webinar on "De-risking product development by using high-resolution mass spectrometry for proteomic characterization" in October, 2021.

Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing

Retrieved on:

Thursday, July 22, 2021

Branches of biology, Parvovirinae, Adeno-associated virus, Parvoviruses, Gene therapy, AAV, Biology, Genetics, Oncolytic AAV

As a fully integrated gene therapy company, Capsida is unique in its end-to-end expertise which includes AAV engineering, cargo development and optimization, translational biology, early capsid manufacturability, clinical development, and state-of-the-art manufacturing.

Key Points:

As a fully integrated gene therapy company, Capsida is unique in its end-to-end expertise which includes AAV engineering, cargo development and optimization, translational biology, early capsid manufacturability, clinical development, and state-of-the-art manufacturing.
"One of our key strategic priorities at Capsida is to create therapies that can be manufactured consistently and rapidly while maintaining the highest quality," said Rayne Waller, chief manufacturing officer of Capsida Biotherapeutics.
"Our new manufacturing facility eliminates the dependence on contract manufacturing which will allow us to bring products seamlessly from discovery into clinical studies faster.
Capsida Biotherapeutics Inc. is developing tissue-targeted gene therapies using its biologically driven, high-throughput adeno-associated virus (AAV) engineering and proprietary cargo development platform.

StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies

Retrieved on:

Wednesday, April 14, 2021

Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Biology, Genetics, Genetic engineering, Applied genetics, Gene delivery, Medical genetics, Molecular biology, AAV, Gene therapy, Adeno-associated virus, Oncolytic AAV

b'StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced the signing of a multi-technology collaboration with Duke University that will enable novel next-generation gene therapies against a broad range of disorders.

Key Points:

b'StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced the signing of a multi-technology collaboration with Duke University that will enable novel next-generation gene therapies against a broad range of disorders.
In addition, StrideBio has licensed exclusive rights covering a novel use of IgG-degrading enzyme IdeZ to clear neutralizing antibodies in conjunction with AAV gene therapy administration.
Our proprietary structure-inspired adeno-associated viral (AAV) vector engineering platform (STRIVE\xe2\x84\xa2) creates unique and differentiated capsids that overcome current limitations of first-generation gene therapies.
Combined with our genetic construct design expertise and in-house manufacturing capability at a 1000L scale, we are well positioned to advance novel best-in-class AAV gene therapies.

Freeline to Present at Upcoming Investor Conferences

Retrieved on:

Tuesday, March 30, 2021

Branches of biology, Biology, Applied genetics, Genetics, Gene delivery, Parvovirinae, Gene therapy, Emerging technologies, Adeno-associated virus, AAV, R. Jude Samulski, Oncolytic AAV

20th Annual Needham Virtual Healthcare Conference on April 13, 2021 where Theresa Heggie will present a Company overview at 8:00 a.m. EDT.

Key Points:

20th Annual Needham Virtual Healthcare Conference on April 13, 2021 where Theresa Heggie will present a Company overview at 8:00 a.m. EDT.
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies.
The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases.
The Companys integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization.

SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids

Retrieved on:

Tuesday, February 23, 2021

SIRION Biotech GmbH , a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.

Key Points:

SIRION Biotech GmbH , a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseases.
The goal of this collaboration is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.
SIRION Biotech was founded in 2005 with the goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccine development.

Dyno Therapeutics Announces Publication in Nature Biotechnology Demonstrating Use of Artificial Intelligence to Generate Unprecedented Diversity of AAV Capsids and Broaden Reach of Gene Therapies

Retrieved on:

Thursday, February 11, 2021

Biotechnology, Pharmaceutical, Health, Branches of biology, Biology, Life sciences, Genetic engineering, Gene delivery, Medical genetics, Molecular biology, Applied genetics, Gene therapy, Therapy, Oncolytic AAV, Viral vector

It is estimated that up to 50-70% of the human population have pre-existing immunity to natural forms of the AAV vectors currently being using to deliver gene therapies.

Key Points:

It is estimated that up to 50-70% of the human population have pre-existing immunity to natural forms of the AAV vectors currently being using to deliver gene therapies.
This immunity renders a large portion of patients ineligible to receive gene therapies which rely upon these capsids as the vector for delivery.
Overcoming the challenge of pre-existing immunity to AAV vectors is therefore a major goal for the gene therapy field.
Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative high-throughput in vivo experiments to gene therapy.

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Expected to Grow at a Significant CAGR of 43.4% During the Study Period 2019-30

Retrieved on:

Monday, January 25, 2021

Branches of biology, Biology, Gene delivery, Applied genetics, Medical genetics, Genetic engineering, Adeno-associated virus, Viral vector, Gene therapy, AAV, Oncolytic AAV, Gene therapy of the human retina

DelveInsight's Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report offers a clear picture of the market position of the AAV vectors in the Gene therapy, emerging pipeline therapies, AAV vector-based Gene Therapy market share occupied by individual diseases, current and forecasted market share in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) for the study period 2017-30.

Key Points:

DelveInsight's Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report offers a clear picture of the market position of the AAV vectors in the Gene therapy, emerging pipeline therapies, AAV vector-based Gene Therapy market share occupied by individual diseases, current and forecasted market share in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) for the study period 2017-30.
rAAV gene therapy strategies include Gene replacement, Gene silencing, Gene addition and Gene editing.
Most of the therapies in the AAV Vector-Based Gene Therapy Market are expected to get launched after 2021.
Out of the several viral vectors, Adeno-associated virus (AAV) vectors are currently among the most frequently used, safest and effective viral vectors for gene therapy delivery.

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Expected to Grow at a Significant CAGR of 43.4% During the Study Period 2019-30

Retrieved on:

Monday, January 25, 2021

DelveInsight's Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report offers a clear picture of the market position of the AAV vectors in the Gene therapy, emerging pipeline therapies, AAV vector-based Gene Therapy market share occupied by individual diseases, current and forecasted market share in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) for the study period 2017-30.

Key Points:

DelveInsight's Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report offers a clear picture of the market position of the AAV vectors in the Gene therapy, emerging pipeline therapies, AAV vector-based Gene Therapy market share occupied by individual diseases, current and forecasted market share in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) for the study period 2017-30.
rAAV gene therapy strategies include Gene replacement, Gene silencing, Gene addition and Gene editing.
Most of the therapies in the AAV Vector-Based Gene Therapy Market are expected to get launched after 2021.
Out of the several viral vectors, Adeno-associated virus (AAV) vectors are currently among the most frequently used, safest and effective viral vectors for gene therapy delivery.

4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery

Retrieved on:

Monday, January 25, 2021

Branches of biology, Biology, Genetics, Applied genetics, Gene delivery, Genetic engineering, Parvovirinae, Adeno-associated virus, AAV, Gene therapy, Oncolytic AAV, Self-complementary adeno-associated virus

LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a systematic review paper entitled The Clinical Landscape for AAV Gene Therapies in Nature Reviews Drug Discovery.

Key Points:

LONDON & BOSTON 4BIO Capital (4BIO or the Group), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a systematic review paper entitled The Clinical Landscape for AAV Gene Therapies in Nature Reviews Drug Discovery.
The review, led by Dr. Dima Kuzmin in collaboration with academics from the University of Oxford and Childrens Hospital of Philadelphia as well as several members of 4BIOs management and advisory teams, analyses 149 unique adeno-associated virus (AAV) gene therapy clinical trials, determining current key trends and depicting the impact of clinical trials on the gene therapy field.
This is the first systematic review and meta-analysis that establishes transition probabilities, cumulative safety, and efficacy data for AAV gene therapies.
The authors show that AAV gene therapy is generally safe and well tolerated, with no clinical trials failing to reach their primary safety endpoints prior to the cut-off date of the review.